SkinBioTherapeutics Plc

Symbol: SBTX.L

LSE

9.32

GBp

Market price today

  • -5.7143

    P/E Ratio

  • 7.0000

    PEG Ratio

  • 18.68M

    MRK Cap

  • 0.00%

    DIV Yield

SkinBioTherapeutics Plc (SBTX-L) Financial Statements

On the chart you can see the default numbers in dynamics for SkinBioTherapeutics Plc (SBTX.L). Companys revenue shows the average of 0.026 M which is 0.038 % gowth. The average gross profit for the whole period is 0.006 M which is 1.080 %. The average gross profit ratio is 0.191 %. The net income growth for the company last year performance is 0.015 % which equals -11.148 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of SkinBioTherapeutics Plc, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.226. In the realm of current assets, SBTX.L clocks in at 1.721 in the reporting currency. A significant portion of these assets, precisely 1.312, is held in cash and short-term investments. This segment shows a change of -0.273% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0.07 in the reporting currency. This figure signifies a year_over_year change of -0.213%. Shareholder value, as depicted by the total shareholder equity, is valued at 1.995 in the reporting currency. The year over year change in this aspect is -0.194%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 0.305, with an inventory valuation of 0.03, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.7.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015

balance-sheet.row.cash-and-short-term-investments

6.721.31.84.6
2.2
3.1
3.2
3.9
0.3

balance-sheet.row.short-term-investments

0000
0
0
0
0
0

balance-sheet.row.net-receivables

1.410.30.30.2
0.1
0.3
0.2
0.2
0

balance-sheet.row.inventory

0.2900.10
0
-0.3
-0.2
0
0

balance-sheet.row.other-current-assets

0.390.10.10.2
0
0.5
0.2
0
0

balance-sheet.row.total-current-assets

8.571.72.35.1
2.3
3.6
3.4
4.1
0.3

balance-sheet.row.property-plant-equipment-net

0.570.20.10.1
0
0
0
0
0

balance-sheet.row.goodwill

0000
0
0
0
0
0

balance-sheet.row.intangible-assets

1.980.70.60.5
0.4
0.3
0.3
0.2
0.1

balance-sheet.row.goodwill-and-intangible-assets

1.980.70.60.5
0.4
0.3
0.3
0.2
0.1

balance-sheet.row.long-term-investments

0000
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0.4
0
0
0
0

balance-sheet.row.other-non-current-assets

-1.63-0.9-0.8-0.7
-0.4
-0.4
-0.3
-0.2
-0.1

balance-sheet.row.total-non-current-assets

3.310.90.80.7
0.4
0.4
0.3
0.2
0.1

balance-sheet.row.other-assets

0000
0
0
0
0
0

balance-sheet.row.total-assets

11.882.63.15.7
2.8
3.9
3.7
4.3
0.4

balance-sheet.row.account-payables

2.110.20.10.1
0.1
0.1
0.1
0.1
0

balance-sheet.row.short-term-debt

0.12000
0
0
0
0
0

balance-sheet.row.tax-payables

0.10.100
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0.250.10.10.1
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-

balance-sheet.row.other-current-liab

0.80.30.40.4
0.2
0.1
0.1
0
0

balance-sheet.row.total-non-current-liabilities

0.310.10.10.1
0
0
0
0.1
0

balance-sheet.row.other-liabilities

0000
0
0
0
-0.1
0

balance-sheet.row.capital-lease-obligations

0.310.10.10.1
0
0
0
0
0

balance-sheet.row.total-liab

2.550.60.60.5
0.3
0.1
0.2
0.1
0

balance-sheet.row.preferred-stock

0000
0
0
0
0
0

balance-sheet.row.common-stock

6.771.71.61.6
1.3
1.3
1.2
1.2
0

balance-sheet.row.retained-earnings

-41.44-11.1-8.3-5.5
-4.1
-2.6
-1.5
-0.6
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

1.770.40.40.4
0.4
0.2
0.2
0.1
0

balance-sheet.row.other-total-stockholders-equity

42.2310.98.88.8
4.9
4.9
3.6
3.6
0.4

balance-sheet.row.total-stockholders-equity

9.3322.55.2
2.5
3.8
3.4
4.2
0.4

balance-sheet.row.total-liabilities-and-stockholders-equity

11.882.63.15.7
2.8
3.9
3.7
4.3
0.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0

balance-sheet.row.total-equity

9.3322.55.2
2.5
3.8
3.4
4.2
0.4

balance-sheet.row.total-liabilities-and-total-equity

11.88---
-
-
-
-
-

Total Investments

0000
0
0
0
0
0

balance-sheet.row.total-debt

0.440.10.10.1
0
0
0
0
0

balance-sheet.row.net-debt

-6.29-1.2-1.7-4.5
-2.2
-3.1
-3.2
-3.9
-0.3

Cash Flow Statement

The financial landscape of SkinBioTherapeutics Plc has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.015. The company recently extended its share capital by issuing 2.35, marking a difference of 10.434 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0.02 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -165277.000 in the reporting currency. This is a shift of 0.707 from the previous year. In the same period, the company recorded 0.04, 0, and -0.04, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 2.32, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015

cash-flows.row.net-income

-5.89-2.8-2.8-1.4
-1.5
-1.1
-0.8
-0.7
0

cash-flows.row.depreciation-and-amortization

0.1000
0
0
0
0
0

cash-flows.row.deferred-income-tax

0.400-0.3
0
0.1
0
0
0

cash-flows.row.stock-based-compensation

0.0300.10.1
0.2
0.1
0.1
0.1
0

cash-flows.row.change-in-working-capital

0.530.10.1-0.1
0.4
-0.1
0.1
0
0

cash-flows.row.account-receivables

0.03-0.10.1-0.2
0.2
-0.1
0.1
-0.1
0

cash-flows.row.inventory

0.370.1-0.10
0
0
0
0
0

cash-flows.row.account-payables

0.1400.10
0
0
0
0
0

cash-flows.row.other-working-capital

0000.1
0.2
0
0
0.1
0

cash-flows.row.other-non-cash-items

-0.460.1-0.10.2
0.1
-0.3
0
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-5.28000
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.3-0.2-0.1-0.1
-0.1
0
-0.1
-0.1
-0.1

cash-flows.row.acquisitions-net

0000
0
0
0
0
0

cash-flows.row.purchases-of-investments

0000
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

0000
0
0
0
0
0

cash-flows.row.other-investing-activites

0000
0
-0.1
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-0.3-0.2-0.1-0.1
-0.1
-0.1
-0.1
-0.1
-0.1

cash-flows.row.debt-repayment

-0.02000
0
0
0
-0.4
0

cash-flows.row.common-stock-issued

5.342.404.1
0
1.4
0
4
0.4

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0

cash-flows.row.other-financing-activites

2.272.304.1
0
1.4
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

5.272.304.1
0
1.4
0
4.4
0.4

cash-flows.row.effect-of-forex-changes-on-cash

-1.31000
0
0
0
0
0

cash-flows.row.net-change-in-cash

-0.31-0.5-2.82.5
-1
-0.1
-0.7
3.7
0.2

cash-flows.row.cash-at-end-of-period

6.721.31.84.6
2.2
3.1
3.2
3.9
0.3

cash-flows.row.cash-at-beginning-of-period

7.041.84.62.2
3.1
3.2
3.9
0.3
0

cash-flows.row.operating-cash-flow

-5.28-2.6-2.7-1.6
-0.9
-1.4
-0.7
-0.6
0

cash-flows.row.capital-expenditure

-0.3-0.2-0.1-0.1
-0.1
0
-0.1
-0.1
-0.1

cash-flows.row.free-cash-flow

-5.58-2.8-2.8-1.7
-1
-1.4
-0.7
-0.7
-0.1

Income Statement Row

SkinBioTherapeutics Plc's revenue saw a change of 0.766% compared with the previous period. The gross profit of SBTX.L is reported to be 0.04. The company's operating expenses are 3.04, showing a change of 1.474% from the last year. The expenses for depreciation and amortization are 0.04, which is a 0.489% change from the last accounting period. Operating expenses are reported to be 3.04, which shows a 1.474% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.104% year-over-year growth. The operating income is -3, which shows a 0.006% change when compared to the previous year. The change in the net income is 0.015%. The net income for the last year was -2.84.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015

income-statement-row.row.total-revenue

0.290.10.10
0
0
0
0
0

income-statement-row.row.cost-of-revenue

0.210.10.10
0
0
0
0
0

income-statement-row.row.gross-profit

0.08000
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0

income-statement-row.row.research-development

1.64---
-
-
-
-
-

income-statement-row.row.selling-general-administrative

3.37---
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0.11---
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0.3
0

income-statement-row.row.operating-expenses

6.29331.5
1.6
1.4
0.9
0.5
0

income-statement-row.row.cost-and-expenses

6.53.13.11.5
1.6
1.4
0.9
0.5
0

income-statement-row.row.interest-income

0.01000
0
0
0
0
0

income-statement-row.row.interest-expense

0.02000
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0.11---
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.02000
0
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0.3
0

income-statement-row.row.total-operating-expenses

-0.02000
0
0
0
0
0

income-statement-row.row.interest-expense

0.02000
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.1000
0
0
0.9
0.2
0

income-statement-row.row.ebitda-caps

-6.1---
-
-
-
-
-

income-statement-row.row.operating-income

-6.21-3-3-1.5
-1.6
-1.4
-0.9
-0.7
0

income-statement-row.row.income-before-tax

-6.23-3-3-1.5
-1.6
-1.4
-0.9
-0.7
0

income-statement-row.row.income-tax-expense

-0.34-0.2-0.2-0.1
-0.1
-0.2
0.1
0
0

income-statement-row.row.net-income

-5.89-2.8-2.8-1.4
-1.5
-1.1
-0.8
-0.6
0

Frequently Asked Question

What is SkinBioTherapeutics Plc (SBTX.L) total assets?

SkinBioTherapeutics Plc (SBTX.L) total assets is 2594252.000.

What is enterprise annual revenue?

The annual revenue is 161648.000.

What is firm profit margin?

Firm profit margin is 0.178.

What is company free cash flow?

The free cash flow is -0.018.

What is enterprise net profit margin?

The net profit margin is -17.847.

What is firm total revenue?

The total revenue is -18.772.

What is SkinBioTherapeutics Plc (SBTX.L) net profit (net income)?

The net profit (net income) is -2835149.000.

What is firm total debt?

The total debt is 100646.000.

What is operating expences number?

The operating expences are 3041056.000.

What is company cash figure?

Enretprise cash is 2840522.000.